Xilio Therapeutics Inc (XLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -58,241 | -45,148 | -31,128 | -17,203 | -76,404 |
| Depreciation Amortization | 1,644 | 1,268 | 888 | 443 | 1,900 |
| Accounts payable and accrued liabilities | 1,526 | -76 | 204 | -305 | -2,063 |
| Other Working Capital | 32,763 | 32,970 | 35,724 | 6,207 | -2,346 |
| Other Operating Activity | 3,930 | 6,765 | 3,763 | 356 | 10,293 |
| Operating Cash Flow | $-18,378 | $-4,221 | $9,451 | $-10,502 | $-68,620 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -36 | -30 | -21 | N/A | -486 |
| Investing Cash Flow | $-36 | $-30 | $-21 | $N/A | $-486 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -3,382 | -3,382 | -3,375 | -3,354 | -6,752 |
| Common Stock Issued | 32,578 | 24,376 | 6,859 | 4,308 | 202 |
| Other Financing Activity | 0 | 0 | 17,513 | 0 | 0 |
| Financing Cash Flow | $29,196 | $20,994 | $20,997 | $954 | $-6,550 |
| Beginning Cash Position | 46,291 | 46,291 | 46,291 | 46,291 | 121,947 |
| End Cash Position | 57,073 | 63,034 | 76,718 | 36,743 | 46,291 |
| Net Cash Flow | $10,782 | $16,743 | $30,427 | $-9,548 | $-75,656 |
| Free Cash Flow | |||||
| Operating Cash Flow | -18,378 | -4,221 | 9,451 | -10,502 | -68,620 |
| Capital Expenditure | -36 | -30 | -21 | N/A | -486 |
| Free Cash Flow | -18,414 | -4,251 | 9,430 | -10,502 | -69,106 |